Security record · archived quarter
DSGN
Design Therapeutics, Inc. · Healthcare · Biotechnology
11Tracked holders
n/aΔ holders
4.24MShares held
$14.20MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 61 | +2 | 14.66M | $212.03M | +5 | −3 |
| Q1 2026 | 61 | +2 | 13.39M | $142.37M | +4 | −2 |
| Q4 2025 | 59 | +1 | 16.55M | $155.25M | +1 | n/a |
| Q3 2025 | 16 | +1 | 10.74M | $80.90M | +1 | n/a |
| Q2 2025 | 12 | -2 | 9.77M | $32.93M | n/a | −2 |
| Q1 2025 | 11 | +2 | 5.33M | $20.59M | +2 | n/a |
| Q4 2024 | 9 | -2 | 5.31M | $32.78M | n/a | −2 |
| Q3 2024 | 10 | -1 | 4.34M | $23.36M | n/a | −1 |
| Q2 2024 | 11 | n/a | 4.24M | $14.20M | n/a | n/a |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 990.80K | n/a | $3.32M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 707.97K | n/a | $2.37M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 610.80K | n/a | $2.05M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 535.78K | n/a | $1.79M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 402.71K | n/a | $1.35M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 384.07K | n/a | $1.29M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 304.63K | n/a | $1.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 256.63K | n/a | $859,700 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 24.28K | n/a | $81,338 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 11.08K | n/a | $37,127 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 11 | T. Rowe Price ✦ | 10.28K | n/a | $35,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 124 holders, 37.97M shares, $395.07M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API